

Joint Working Executive Summary

Joint working partners	The Bristol Heart Institute (BHI), constituent department of University Hospitals Bristol and Weston NHS Foundation Trust (UHBW), and Recordati Pharmaceuticals Ltd
Project period	12 months
Project name	The Bristol Heart Institute Secondary Prevention Clinic
Joint working project summary	<p>The rationale for this project is to continue to provide a Cardiovascular Risk Reduction Clinic for Secondary Prevention patients who have been treated for their atherosclerotic cardiovascular disease (ASCVD) by the Bristol Heart Institute. This project was at risk due to the ending of its previous funding.</p> <p>The project aims to reduce patients' risk of future ASCVD events by –</p> <ol style="list-style-type: none">1) Maintaining the secondary prevention clinic. This clinic, staffed by a team experienced in ASCVD treatment and supervised by a Consultant Cardiologist, aims to ensure that BHI patients are optimised on medical therapy. The team works to the BHI approved treatment protocols with the goal of reducing patients risk of future ASCVD events such as heart attack or stroke. The clinic offers follow up appointments to patients to allow them to be optimised on medications prior to final discharge to primary care during the first year post an ASCVD event. This reduces the burden of management on primary care whilst also giving patients the benefit of additional specialist Cardiology input at this critical time. National, International and local guidelines all stress the importance of optimising care for multiple ASCVD risk factors but data, including CVD Prevent1, shows that the UK healthcare system struggles to get patients optimised on ASCVD risk factor modifying treatments.2) To maximise the benefits of the project, the team will also work with Recordati to run educational meetings for Primary Care in their referral area. ASCVD management is an area that has undergone significant changes over the last 5 years with many new treatments and pathways. These meetings will aim to assist primary care with managing patients long term ASCVD risk.

Joint Working Executive Summary

	<p>3) The BHI team have already put together a data environment that allows the team to longitudinally track patients through Bristol, North Somerset and South Gloucestershire Integrated Care Board (BNSSG ICB). This allows the team to analyse the number and cost of interventions on each patient across primary, secondary, tertiary and social care. The team are working with the BNSSG ICB team to examine the cost effectiveness of the BHI Secondary Prevention Clinic approach compared to the baseline before the clinic started. This should allow the team to look at both the efficacy and cost efficacy of treating patients to their guideline targets across all their manageable ASCVD risk factors.</p> <p>4) The data collected from this project will be used to create a business case to gain continuation funding from the ICB or other sources to include the clinic long term as business as usual.</p> <p>The project supports the BHI with additional Band 7 and Band 6 Nurse time as well as covering the costs of the blood tests and administration to provide the clinic. The BHI will be providing the facilities, IT systems and expertise to identify and review patients.</p> <p>Recordati contact: Ben Cook, National Partnerships Manager. Email : ben.cook@recordati.com</p>
<p>Expected outcomes</p>	<p><u>Patients</u></p> <ul style="list-style-type: none"> • Improved clinical care for Patients, through identification of at-risk Patients and holistic optimisation of ASCVD risk reduction therapies by an expert Cardiac Nursing team. • Optimised medical management is expected to lead to lower levels of future ASCVD event for patients. • Greater satisfaction of Patients discharged from the Collaborator due to greater follow up provision. <p>NHS and Bristol Heart Institute (BHI)</p> <ul style="list-style-type: none"> • The Service will lead to reduction in recurrent cardiac events, with eventual medium and long-term saving for NHS and reduction in

Joint Working Executive Summary

	<p>the downstream burden on the health system (e.g. hospitalisation) from recurrent cardiac events.</p> <ul style="list-style-type: none">• Increased numbers of patients achieving CV risk factor targets.• Better visibility of the costs and benefits of optimised secondary prevention ASCVD risk reduction across a large integrated system; which will be able to inform the resource allocation debate in BNSSG and the wider NHS. <p><u>Recordati Pharmaceuticals Limited</u></p> <ul style="list-style-type: none">• Increase in the appropriate use of medicines aligned with local or national guidance.• Increase in Patients identified for and treated for secondary CVD risk factors, which may be relevant to the Recordati business.• Better understanding of the costs and benefits of implementing a ASCVD risk reduction pathway in an ICB health economy.
Project timeframe	Project commenced April 2025.
Resource contribution	<p>The financial contribution by Recordati is £154,155.67 which has been based on the costs to provide the staff and support for the clinical time as calculated based on the Agenda for Change pay scales and BHI costs.</p> <p>The BHI are covering the costs of providing all the accommodation, training and supervision for the clinic and clinical staff. BHI are also providing the software, databases and expertise for the identification of patients, analysis of the data across the whole health economy as well as the time taken to perform the analysis and build the business cases for a business-as-usual service.</p>